The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment ...
The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new ...
The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.
The Dutch biotech Synaffix and the Swiss company BigHat Biosciences announced yesterday that they have entered into a ...
A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% ...
At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the ...
A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% increase in therapy initiation, driven by AI-enabled patient outreach and ...
The U.S. contract development and manufacturing organization (CDMO) Abzena announced yesterday that it has significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback